| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 466 | 2024 | 11039 | 25.600 |
Why?
|
| Prostate-Specific Antigen | 247 | 2024 | 2458 | 25.100 |
Why?
|
| Androgen Antagonists | 118 | 2024 | 1350 | 18.120 |
Why?
|
| Prostatectomy | 152 | 2023 | 1871 | 12.780 |
Why?
|
| Brachytherapy | 105 | 2024 | 1246 | 12.420 |
Why?
|
| Antineoplastic Agents, Hormonal | 59 | 2021 | 1509 | 7.720 |
Why?
|
| Prostate | 72 | 2023 | 1764 | 5.690 |
Why?
|
| Salvage Therapy | 28 | 2023 | 1269 | 4.530 |
Why?
|
| Adenocarcinoma | 64 | 2021 | 6347 | 3.700 |
Why?
|
| Radiotherapy, Conformal | 22 | 2014 | 548 | 2.700 |
Why?
|
| Male | 506 | 2024 | 349538 | 2.390 |
Why?
|
| Neoplasm Recurrence, Local | 53 | 2023 | 9185 | 2.370 |
Why?
|
| Neoplasm Staging | 102 | 2021 | 11001 | 2.300 |
Why?
|
| Radiotherapy | 23 | 2021 | 1525 | 2.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 16 | 2016 | 1185 | 1.900 |
Why?
|
| Radiotherapy, Adjuvant | 26 | 2022 | 1769 | 1.850 |
Why?
|
| Cause of Death | 38 | 2020 | 3571 | 1.830 |
Why?
|
| Flutamide | 10 | 2012 | 96 | 1.750 |
Why?
|
| Aged | 249 | 2023 | 162944 | 1.730 |
Why?
|
| Combined Modality Therapy | 51 | 2021 | 8621 | 1.690 |
Why?
|
| Testosterone | 9 | 2021 | 2401 | 1.600 |
Why?
|
| Radiotherapy Dosage | 30 | 2024 | 2876 | 1.560 |
Why?
|
| Humans | 517 | 2024 | 742088 | 1.550 |
Why?
|
| Watchful Waiting | 9 | 2020 | 491 | 1.530 |
Why?
|
| Kallikreins | 7 | 2021 | 258 | 1.510 |
Why?
|
| Digital Rectal Examination | 4 | 2014 | 42 | 1.450 |
Why?
|
| Biopsy | 52 | 2021 | 6756 | 1.440 |
Why?
|
| Follow-Up Studies | 95 | 2020 | 39004 | 1.390 |
Why?
|
| Proportional Hazards Models | 51 | 2021 | 12344 | 1.330 |
Why?
|
| Risk Assessment | 72 | 2022 | 23320 | 1.310 |
Why?
|
| Middle Aged | 225 | 2023 | 213127 | 1.280 |
Why?
|
| Risk Factors | 115 | 2021 | 72145 | 1.260 |
Why?
|
| Regression Analysis | 37 | 2016 | 6452 | 1.260 |
Why?
|
| Prognosis | 83 | 2020 | 29010 | 1.230 |
Why?
|
| Early Detection of Cancer | 14 | 2023 | 3070 | 1.190 |
Why?
|
| Orchiectomy | 8 | 2016 | 466 | 1.100 |
Why?
|
| Rectum | 20 | 2014 | 903 | 1.100 |
Why?
|
| Patient Selection | 24 | 2016 | 4214 | 1.070 |
Why?
|
| Radiosurgery | 7 | 2023 | 1309 | 1.060 |
Why?
|
| Aged, 80 and over | 95 | 2023 | 57683 | 1.060 |
Why?
|
| Radiation Injuries | 13 | 2019 | 1178 | 1.030 |
Why?
|
| Survival Analysis | 40 | 2020 | 10248 | 1.030 |
Why?
|
| Seminal Vesicles | 11 | 2006 | 101 | 1.000 |
Why?
|
| Time Factors | 61 | 2021 | 40054 | 0.970 |
Why?
|
| Neoplasms, Hormone-Dependent | 6 | 2009 | 414 | 0.960 |
Why?
|
| Multivariate Analysis | 49 | 2015 | 12242 | 0.960 |
Why?
|
| Magnetic Resonance Imaging | 51 | 2023 | 35342 | 0.950 |
Why?
|
| Survival Rate | 39 | 2020 | 12773 | 0.950 |
Why?
|
| Urination Disorders | 5 | 2014 | 241 | 0.910 |
Why?
|
| Rectal Diseases | 3 | 2012 | 142 | 0.910 |
Why?
|
| Treatment Outcome | 84 | 2021 | 62966 | 0.860 |
Why?
|
| Disease-Free Survival | 39 | 2018 | 6891 | 0.860 |
Why?
|
| Treatment Failure | 25 | 2015 | 2615 | 0.850 |
Why?
|
| Comorbidity | 23 | 2018 | 10372 | 0.840 |
Why?
|
| Biopsy, Needle | 13 | 2014 | 1640 | 0.810 |
Why?
|
| Prospective Studies | 46 | 2023 | 53187 | 0.780 |
Why?
|
| Chemotherapy, Adjuvant | 19 | 2019 | 3471 | 0.730 |
Why?
|
| Predictive Value of Tests | 51 | 2020 | 15056 | 0.720 |
Why?
|
| Androstenes | 2 | 2017 | 169 | 0.680 |
Why?
|
| Risk | 22 | 2021 | 9679 | 0.670 |
Why?
|
| Age Factors | 26 | 2020 | 18355 | 0.670 |
Why?
|
| Androgens | 9 | 2024 | 1271 | 0.670 |
Why?
|
| Lymph Node Excision | 10 | 2019 | 1248 | 0.650 |
Why?
|
| Leuprolide | 9 | 2014 | 303 | 0.640 |
Why?
|
| Neoplasm Metastasis | 12 | 2021 | 4839 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 22 | 2023 | 9941 | 0.630 |
Why?
|
| Cohort Studies | 49 | 2022 | 40450 | 0.630 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2021 | 806 | 0.620 |
Why?
|
| Decision Support Techniques | 6 | 2015 | 1952 | 0.590 |
Why?
|
| Goserelin | 8 | 2014 | 127 | 0.580 |
Why?
|
| Emotions | 4 | 2020 | 2657 | 0.570 |
Why?
|
| Quality of Life | 20 | 2019 | 12730 | 0.550 |
Why?
|
| Finasteride | 2 | 2007 | 89 | 0.540 |
Why?
|
| Neoplasm Invasiveness | 21 | 2015 | 3612 | 0.520 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2015 | 113 | 0.520 |
Why?
|
| Luteinizing Hormone | 2 | 2015 | 864 | 0.510 |
Why?
|
| Mass Screening | 9 | 2023 | 5238 | 0.510 |
Why?
|
| Radiotherapy, High-Energy | 6 | 2014 | 228 | 0.500 |
Why?
|
| Cardiovascular Diseases | 14 | 2018 | 15108 | 0.500 |
Why?
|
| Iodine Radioisotopes | 8 | 2013 | 1030 | 0.490 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2007 | 1130 | 0.490 |
Why?
|
| Tosyl Compounds | 2 | 2012 | 110 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11472 | 0.480 |
Why?
|
| Retrospective Studies | 67 | 2023 | 77098 | 0.480 |
Why?
|
| Myocardial Infarction | 10 | 2016 | 11690 | 0.470 |
Why?
|
| Pelvis | 7 | 2022 | 730 | 0.470 |
Why?
|
| Germany | 3 | 2021 | 860 | 0.460 |
Why?
|
| Lymphatic Metastasis | 7 | 2021 | 2906 | 0.460 |
Why?
|
| Carcinoma | 7 | 2007 | 2374 | 0.460 |
Why?
|
| Life Expectancy | 6 | 2015 | 1183 | 0.460 |
Why?
|
| Neoadjuvant Therapy | 10 | 2016 | 2721 | 0.450 |
Why?
|
| Confidence Intervals | 9 | 2016 | 2970 | 0.440 |
Why?
|
| Nitriles | 3 | 2013 | 952 | 0.420 |
Why?
|
| Seminoma | 2 | 2015 | 136 | 0.420 |
Why?
|
| Urinary Retention | 2 | 2005 | 110 | 0.410 |
Why?
|
| Antineoplastic Agents | 13 | 2022 | 13655 | 0.410 |
Why?
|
| SEER Program | 15 | 2019 | 1507 | 0.410 |
Why?
|
| Testicular Neoplasms | 4 | 2015 | 761 | 0.400 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 214 | 0.400 |
Why?
|
| Anilides | 2 | 2012 | 404 | 0.400 |
Why?
|
| Breath Tests | 1 | 2012 | 276 | 0.380 |
Why?
|
| Volatile Organic Compounds | 1 | 2012 | 81 | 0.380 |
Why?
|
| Prostatic Hyperplasia | 6 | 2019 | 522 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 11 | 2019 | 7276 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 3239 | 0.350 |
Why?
|
| Tumor Burden | 4 | 2023 | 1905 | 0.350 |
Why?
|
| Health Status | 4 | 2014 | 4030 | 0.340 |
Why?
|
| Coronary Artery Disease | 4 | 2013 | 6454 | 0.340 |
Why?
|
| United States | 39 | 2021 | 69693 | 0.340 |
Why?
|
| Acetanilides | 1 | 2010 | 168 | 0.340 |
Why?
|
| Clindamycin | 1 | 2009 | 139 | 0.330 |
Why?
|
| Hypercholesterolemia | 3 | 2013 | 1149 | 0.330 |
Why?
|
| Radium | 3 | 2020 | 65 | 0.330 |
Why?
|
| Chromatography, Gas | 1 | 2008 | 156 | 0.320 |
Why?
|
| Algorithms | 8 | 2021 | 13853 | 0.310 |
Why?
|
| Radiation Dosage | 6 | 2021 | 1927 | 0.310 |
Why?
|
| Drug Approval | 2 | 2013 | 740 | 0.310 |
Why?
|
| Estrogens | 1 | 2014 | 1562 | 0.300 |
Why?
|
| Defecation | 2 | 2006 | 188 | 0.300 |
Why?
|
| Urethra | 4 | 2021 | 408 | 0.300 |
Why?
|
| Myocardial Revascularization | 1 | 2011 | 841 | 0.290 |
Why?
|
| Transducers | 1 | 2008 | 252 | 0.290 |
Why?
|
| Databases, Factual | 10 | 2021 | 7716 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 6534 | 0.280 |
Why?
|
| Lymph Nodes | 6 | 2021 | 3465 | 0.280 |
Why?
|
| Angina Pectoris | 1 | 2010 | 977 | 0.270 |
Why?
|
| Skin Tests | 1 | 2008 | 612 | 0.270 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 3800 | 0.270 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2009 | 638 | 0.270 |
Why?
|
| Guideline Adherence | 3 | 2013 | 2266 | 0.270 |
Why?
|
| Hemorrhoids | 1 | 2005 | 20 | 0.270 |
Why?
|
| Age of Onset | 5 | 2015 | 3266 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3130 | 0.260 |
Why?
|
| Probiotics | 1 | 2009 | 351 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3236 | 0.260 |
Why?
|
| Erectile Dysfunction | 6 | 2010 | 459 | 0.260 |
Why?
|
| Radiodermatitis | 1 | 2005 | 60 | 0.260 |
Why?
|
| Preoperative Care | 8 | 2009 | 2245 | 0.260 |
Why?
|
| Actuarial Analysis | 7 | 2001 | 377 | 0.250 |
Why?
|
| Markov Chains | 3 | 2020 | 969 | 0.250 |
Why?
|
| Logistic Models | 15 | 2019 | 13403 | 0.250 |
Why?
|
| Clinical Trials as Topic | 13 | 2021 | 7901 | 0.250 |
Why?
|
| Computer Systems | 3 | 2003 | 483 | 0.250 |
Why?
|
| Propensity Score | 5 | 2021 | 1771 | 0.250 |
Why?
|
| Adult | 57 | 2021 | 213712 | 0.240 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2013 | 256 | 0.240 |
Why?
|
| Disease Progression | 12 | 2021 | 13256 | 0.240 |
Why?
|
| Diabetes Complications | 1 | 2011 | 1359 | 0.240 |
Why?
|
| Radiometry | 5 | 2016 | 800 | 0.240 |
Why?
|
| Australia | 2 | 2021 | 1167 | 0.240 |
Why?
|
| Recurrence | 9 | 2013 | 8333 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1052 | 0.230 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 848 | 0.230 |
Why?
|
| Radiation Oncology | 3 | 2019 | 554 | 0.230 |
Why?
|
| Heart Diseases | 4 | 2019 | 2789 | 0.230 |
Why?
|
| Urinary Bladder | 5 | 2003 | 1171 | 0.230 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 6483 | 0.230 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2019 | 106 | 0.220 |
Why?
|
| BRCA2 Protein | 2 | 2019 | 790 | 0.220 |
Why?
|
| Alopecia | 1 | 2007 | 381 | 0.220 |
Why?
|
| Sensitivity and Specificity | 15 | 2014 | 14720 | 0.220 |
Why?
|
| Radioisotopes | 3 | 2013 | 499 | 0.210 |
Why?
|
| Self Medication | 1 | 2002 | 117 | 0.210 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 1364 | 0.210 |
Why?
|
| Odds Ratio | 11 | 2019 | 9846 | 0.210 |
Why?
|
| Niacin | 1 | 2002 | 116 | 0.210 |
Why?
|
| Belgium | 1 | 2021 | 103 | 0.200 |
Why?
|
| Heart Failure | 5 | 2013 | 10856 | 0.200 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 5169 | 0.200 |
Why?
|
| Advisory Committees | 2 | 2019 | 773 | 0.200 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 1622 | 0.200 |
Why?
|
| Reproducibility of Results | 23 | 2014 | 19862 | 0.190 |
Why?
|
| Coronary Artery Bypass | 1 | 2010 | 2281 | 0.190 |
Why?
|
| New Zealand | 1 | 2021 | 357 | 0.190 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2001 | 123 | 0.190 |
Why?
|
| Flank Pain | 1 | 2000 | 43 | 0.190 |
Why?
|
| Career Choice | 1 | 2007 | 743 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2276 | 0.180 |
Why?
|
| Prostatic Diseases | 1 | 2000 | 56 | 0.180 |
Why?
|
| Urethritis | 1 | 1999 | 22 | 0.180 |
Why?
|
| Aspirin | 2 | 2012 | 3278 | 0.180 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 1999 | 25 | 0.180 |
Why?
|
| Chi-Square Distribution | 5 | 2018 | 3510 | 0.180 |
Why?
|
| Forecasting | 8 | 2005 | 2948 | 0.180 |
Why?
|
| Stroke | 2 | 2014 | 9963 | 0.180 |
Why?
|
| Healthcare Disparities | 5 | 2014 | 3151 | 0.180 |
Why?
|
| Hemibody Irradiation | 1 | 2019 | 4 | 0.180 |
Why?
|
| Piperazines | 1 | 2010 | 2488 | 0.180 |
Why?
|
| Postoperative Complications | 9 | 2014 | 15244 | 0.170 |
Why?
|
| Pathology, Clinical | 1 | 2003 | 368 | 0.170 |
Why?
|
| Kidney Pelvis | 1 | 2000 | 188 | 0.170 |
Why?
|
| Hemoglobins | 2 | 2002 | 1532 | 0.170 |
Why?
|
| Hematuria | 1 | 2000 | 235 | 0.170 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 248 | 0.170 |
Why?
|
| Teaching | 1 | 2007 | 1174 | 0.170 |
Why?
|
| Illinois | 1 | 2019 | 119 | 0.170 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 2 | 2013 | 108 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 4029 | 0.160 |
Why?
|
| Faculty, Medical | 1 | 2007 | 1182 | 0.160 |
Why?
|
| Incidence | 12 | 2023 | 20928 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2016 | 1679 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2002 | 1458 | 0.160 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 1997 | 18 | 0.150 |
Why?
|
| Genomics | 3 | 2019 | 5692 | 0.150 |
Why?
|
| Analysis of Variance | 8 | 2013 | 6365 | 0.150 |
Why?
|
| Patient Satisfaction | 4 | 2013 | 3391 | 0.150 |
Why?
|
| Thallium Radioisotopes | 1 | 1997 | 139 | 0.150 |
Why?
|
| ROC Curve | 5 | 2014 | 3528 | 0.150 |
Why?
|
| Diabetes Mellitus | 3 | 2013 | 5724 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 2948 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2020 | 600 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2021 | 546 | 0.150 |
Why?
|
| Unnecessary Procedures | 2 | 2011 | 431 | 0.150 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1997 | 84 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3336 | 0.140 |
Why?
|
| Patient Participation | 2 | 2023 | 1445 | 0.140 |
Why?
|
| Tissue Extracts | 2 | 2013 | 135 | 0.140 |
Why?
|
| Lip Neoplasms | 1 | 1996 | 37 | 0.140 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1996 | 41 | 0.140 |
Why?
|
| Cardiac Myosins | 1 | 2016 | 117 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 1167 | 0.140 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2016 | 71 | 0.140 |
Why?
|
| Urinary Incontinence | 4 | 2009 | 494 | 0.130 |
Why?
|
| Genital Neoplasms, Male | 3 | 2006 | 74 | 0.130 |
Why?
|
| Societies, Medical | 4 | 2019 | 3740 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2023 | 8297 | 0.130 |
Why?
|
| Immobilization | 3 | 2012 | 236 | 0.130 |
Why?
|
| Carcinoma, Embryonal | 1 | 2015 | 38 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 7770 | 0.130 |
Why?
|
| Patient Care | 1 | 2021 | 639 | 0.130 |
Why?
|
| Patient Care Planning | 3 | 2004 | 921 | 0.130 |
Why?
|
| Catheterization | 3 | 2012 | 1468 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2010 | 12695 | 0.130 |
Why?
|
| Chicago | 1 | 2015 | 238 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 13019 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2019 | 575 | 0.120 |
Why?
|
| Myosin Heavy Chains | 1 | 2016 | 414 | 0.120 |
Why?
|
| Urogenital System | 2 | 2023 | 86 | 0.120 |
Why?
|
| Contrast Media | 2 | 2005 | 5295 | 0.120 |
Why?
|
| Postoperative Period | 4 | 2010 | 1839 | 0.120 |
Why?
|
| Androstenols | 1 | 2013 | 25 | 0.120 |
Why?
|
| Evidence-Based Medicine | 5 | 2014 | 3611 | 0.120 |
Why?
|
| Estramustine | 1 | 2013 | 35 | 0.120 |
Why?
|
| Disability Evaluation | 2 | 2014 | 1827 | 0.120 |
Why?
|
| Penis | 3 | 2013 | 216 | 0.120 |
Why?
|
| Kinetics | 4 | 2019 | 6474 | 0.120 |
Why?
|
| Fecal Incontinence | 2 | 2009 | 240 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 987 | 0.120 |
Why?
|
| Lewy Body Disease | 1 | 2016 | 226 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2010 | 719 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2006 | 3123 | 0.120 |
Why?
|
| Mitoxantrone | 1 | 2013 | 149 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 6754 | 0.120 |
Why?
|
| Life Tables | 2 | 2004 | 370 | 0.120 |
Why?
|
| Taxoids | 2 | 2013 | 665 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 4929 | 0.110 |
Why?
|
| Kidney Neoplasms | 6 | 2006 | 4229 | 0.110 |
Why?
|
| Probability | 4 | 2022 | 2502 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1145 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2000 | 1426 | 0.110 |
Why?
|
| Metformin | 1 | 2020 | 829 | 0.110 |
Why?
|
| Metabolome | 1 | 2019 | 881 | 0.110 |
Why?
|
| Insurance Coverage | 2 | 2014 | 1895 | 0.110 |
Why?
|
| Prostheses and Implants | 2 | 2011 | 1385 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2020 | 2229 | 0.110 |
Why?
|
| Dystroglycans | 1 | 2012 | 60 | 0.110 |
Why?
|
| Anuria | 1 | 1992 | 15 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2019 | 795 | 0.110 |
Why?
|
| Phenylthiohydantoin | 1 | 2013 | 192 | 0.110 |
Why?
|
| Health Status Disparities | 2 | 2014 | 1794 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1997 | 1107 | 0.100 |
Why?
|
| Spermatic Cord Torsion | 1 | 1992 | 73 | 0.100 |
Why?
|
| Pandemics | 3 | 2021 | 8328 | 0.100 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 325 | 0.100 |
Why?
|
| Liver | 1 | 2007 | 7470 | 0.100 |
Why?
|
| Organs at Risk | 1 | 2014 | 346 | 0.100 |
Why?
|
| Organ Size | 3 | 2013 | 2253 | 0.100 |
Why?
|
| Medical Oncology | 3 | 2014 | 2235 | 0.100 |
Why?
|
| Muscular Diseases | 1 | 2016 | 557 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2303 | 0.100 |
Why?
|
| Observer Variation | 4 | 2009 | 2593 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 1195 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 3691 | 0.100 |
Why?
|
| Cyproterone Acetate | 1 | 2010 | 6 | 0.100 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 361 | 0.100 |
Why?
|
| Exhalation | 1 | 2012 | 166 | 0.100 |
Why?
|
| Gastrointestinal Tract | 2 | 2009 | 814 | 0.100 |
Why?
|
| Decision Making | 2 | 2023 | 3869 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 7153 | 0.100 |
Why?
|
| Reference Values | 4 | 2010 | 4982 | 0.090 |
Why?
|
| Mucus | 1 | 2012 | 321 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 2211 | 0.090 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2014 | 258 | 0.090 |
Why?
|
| Referral and Consultation | 3 | 2019 | 3527 | 0.090 |
Why?
|
| Neoplasms | 6 | 2020 | 21596 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2011 | 587 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2012 | 319 | 0.090 |
Why?
|
| Population Surveillance | 3 | 2015 | 2616 | 0.090 |
Why?
|
| Cesium Radioisotopes | 1 | 2009 | 36 | 0.090 |
Why?
|
| Sulfonamides | 1 | 1999 | 1932 | 0.090 |
Why?
|
| Boston | 2 | 2021 | 9305 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2019 | 2051 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 1676 | 0.090 |
Why?
|
| Muscular Dystrophies | 1 | 2012 | 393 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 484 | 0.090 |
Why?
|
| Health Literacy | 1 | 2015 | 414 | 0.090 |
Why?
|
| Melanoma | 1 | 2008 | 5462 | 0.090 |
Why?
|
| Massachusetts | 3 | 2009 | 8662 | 0.090 |
Why?
|
| Penile Neoplasms | 3 | 2000 | 159 | 0.090 |
Why?
|
| Palladium | 1 | 2009 | 65 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2020 | 21719 | 0.090 |
Why?
|
| Edema | 1 | 2013 | 790 | 0.080 |
Why?
|
| Interleukins | 1 | 2013 | 791 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2013 | 625 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
| Respiratory System | 1 | 2012 | 555 | 0.080 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2010 | 183 | 0.080 |
Why?
|
| Walking | 3 | 2013 | 1177 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2010 | 7988 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2013 | 904 | 0.080 |
Why?
|
| Drug Design | 2 | 2004 | 1078 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2011 | 981 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 5662 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2231 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2013 | 1176 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 401 | 0.080 |
Why?
|
| Benzamides | 1 | 2013 | 1378 | 0.080 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 448 | 0.080 |
Why?
|
| Arachidonic Acids | 1 | 2008 | 299 | 0.080 |
Why?
|
| Angioplasty | 1 | 2010 | 364 | 0.080 |
Why?
|
| Self Report | 2 | 2020 | 3548 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 11695 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2009 | 358 | 0.080 |
Why?
|
| Gases | 1 | 2008 | 197 | 0.080 |
Why?
|
| Fertility | 1 | 1992 | 770 | 0.080 |
Why?
|
| Imidazoles | 1 | 2013 | 1205 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2009 | 181 | 0.070 |
Why?
|
| Diarrhea | 2 | 2012 | 1343 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 3957 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 1342 | 0.070 |
Why?
|
| Penile Erection | 1 | 2006 | 97 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2007 | 5774 | 0.070 |
Why?
|
| Otitis Media | 1 | 1989 | 277 | 0.070 |
Why?
|
| Female | 28 | 2021 | 379592 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1369 | 0.070 |
Why?
|
| Bone Marrow | 1 | 1997 | 2941 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 2417 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
| Adolescent | 14 | 2020 | 85649 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2007 | 528 | 0.070 |
Why?
|
| Registries | 3 | 2011 | 8077 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 17400 | 0.070 |
Why?
|
| Feasibility Studies | 5 | 2023 | 5062 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2023 | 3760 | 0.070 |
Why?
|
| Granuloma | 1 | 2008 | 315 | 0.070 |
Why?
|
| Electromagnetic Phenomena | 1 | 2007 | 161 | 0.070 |
Why?
|
| Patient Care Team | 2 | 2019 | 2527 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 1581 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 343 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 12958 | 0.070 |
Why?
|
| Exercise Test | 1 | 2013 | 2075 | 0.070 |
Why?
|
| Income | 1 | 2014 | 1904 | 0.070 |
Why?
|
| Urination | 1 | 2006 | 204 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2009 | 1661 | 0.070 |
Why?
|
| Software | 1 | 2000 | 4434 | 0.070 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 867 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2012 | 1059 | 0.070 |
Why?
|
| Mobility Limitation | 1 | 2009 | 405 | 0.060 |
Why?
|
| Thrombin | 1 | 1988 | 598 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 3507 | 0.060 |
Why?
|
| Tourette Syndrome | 1 | 2008 | 379 | 0.060 |
Why?
|
| Urogenital Neoplasms | 1 | 2006 | 135 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1889 | 0.060 |
Why?
|
| Heart | 3 | 2019 | 4462 | 0.060 |
Why?
|
| Career Mobility | 1 | 2007 | 262 | 0.060 |
Why?
|
| Models, Biological | 2 | 2005 | 9581 | 0.060 |
Why?
|
| Hypertension | 3 | 2013 | 8455 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 2867 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1436 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.060 |
Why?
|
| Prevalence | 4 | 2020 | 15194 | 0.060 |
Why?
|
| Palpation | 2 | 2001 | 166 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 2684 | 0.060 |
Why?
|
| Urethral Obstruction | 1 | 2003 | 56 | 0.060 |
Why?
|
| Motor Activity | 1 | 2014 | 2714 | 0.060 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 13921 | 0.060 |
Why?
|
| Italy | 3 | 2013 | 828 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2013 | 1194 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8425 | 0.060 |
Why?
|
| Middle East | 1 | 2023 | 219 | 0.060 |
Why?
|
| Receptors, LHRH | 1 | 2003 | 159 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 627 | 0.060 |
Why?
|
| Precipitating Factors | 1 | 2002 | 52 | 0.050 |
Why?
|
| Proctitis | 1 | 2002 | 40 | 0.050 |
Why?
|
| Linear Models | 3 | 2007 | 5948 | 0.050 |
Why?
|
| Intraoperative Care | 2 | 2003 | 766 | 0.050 |
Why?
|
| Europe | 2 | 2023 | 3339 | 0.050 |
Why?
|
| Ejaculation | 1 | 2002 | 58 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2002 | 119 | 0.050 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 1402 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2009 | 1484 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2009 | 924 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1989 | 770 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 3058 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2012 | 8925 | 0.050 |
Why?
|
| Robotics | 1 | 2010 | 892 | 0.050 |
Why?
|
| Anal Canal | 1 | 2005 | 376 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 1988 | 1274 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3584 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2014 | 3738 | 0.050 |
Why?
|
| Acetylglucosaminidase | 1 | 2001 | 70 | 0.050 |
Why?
|
| Marital Status | 2 | 2015 | 437 | 0.050 |
Why?
|
| Radiography | 3 | 2006 | 7010 | 0.050 |
Why?
|
| Equipment Design | 2 | 2008 | 3582 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2016 | 5100 | 0.050 |
Why?
|
| Biosensing Techniques | 1 | 2008 | 668 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2014 | 2493 | 0.050 |
Why?
|
| Mentors | 1 | 2007 | 630 | 0.050 |
Why?
|
| Health Services Research | 1 | 2009 | 1834 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 1473 | 0.050 |
Why?
|
| Software Validation | 1 | 2001 | 59 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5171 | 0.050 |
Why?
|
| Delphi Technique | 2 | 2014 | 778 | 0.050 |
Why?
|
| Selection Bias | 1 | 2003 | 369 | 0.050 |
Why?
|
| Young Adult | 9 | 2020 | 56350 | 0.050 |
Why?
|
| Laparoscopy | 2 | 2010 | 2121 | 0.050 |
Why?
|
| Radiation Protection | 1 | 2005 | 419 | 0.050 |
Why?
|
| Child, Preschool | 9 | 2016 | 40955 | 0.050 |
Why?
|
| Pyrroles | 1 | 2007 | 1143 | 0.050 |
Why?
|
| Germinoma | 1 | 2001 | 133 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 605 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 2027 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2006 | 851 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 876 | 0.050 |
Why?
|
| Renal Veins | 1 | 2001 | 108 | 0.050 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 24913 | 0.050 |
Why?
|
| Calibration | 2 | 2000 | 815 | 0.050 |
Why?
|
| North America | 1 | 2023 | 1249 | 0.050 |
Why?
|
| Urology | 2 | 2019 | 397 | 0.040 |
Why?
|
| Morbidity | 2 | 2019 | 1767 | 0.040 |
Why?
|
| Indoles | 1 | 2008 | 1834 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 975 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2014 | 6078 | 0.040 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2000 | 94 | 0.040 |
Why?
|
| Depression | 2 | 2018 | 7733 | 0.040 |
Why?
|
| Hormones | 1 | 2023 | 884 | 0.040 |
Why?
|
| Peritoneum | 1 | 2000 | 226 | 0.040 |
Why?
|
| Mutation | 3 | 2019 | 29717 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 175 | 0.040 |
Why?
|
| Cytokines | 1 | 2013 | 7317 | 0.040 |
Why?
|
| Prodrugs | 1 | 2000 | 268 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2010 | 1945 | 0.040 |
Why?
|
| Perineum | 1 | 2000 | 211 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2023 | 1663 | 0.040 |
Why?
|
| Stents | 1 | 2010 | 3276 | 0.040 |
Why?
|
| Apoptosis | 1 | 1994 | 9715 | 0.040 |
Why?
|
| Benchmarking | 2 | 2018 | 1038 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2020 | 370 | 0.040 |
Why?
|
| Tomography | 1 | 2000 | 388 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 2633 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2001 | 436 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1895 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2006 | 5163 | 0.040 |
Why?
|
| Genes, p16 | 1 | 1997 | 157 | 0.040 |
Why?
|
| Epilepsy | 1 | 2013 | 3301 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 526 | 0.040 |
Why?
|
| California | 1 | 2021 | 1400 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2012 | 4595 | 0.040 |
Why?
|
| Nephrectomy | 2 | 2001 | 1049 | 0.040 |
Why?
|
| Standard of Care | 1 | 2021 | 562 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 1999 | 538 | 0.040 |
Why?
|
| Cell Division | 2 | 1994 | 4564 | 0.030 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1997 | 104 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 8829 | 0.030 |
Why?
|
| Child | 9 | 2016 | 77478 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2000 | 316 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2021 | 681 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 640 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 2 | 2002 | 744 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 3915 | 0.030 |
Why?
|
| Mortality | 2 | 2019 | 2857 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 5304 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 1999 | 824 | 0.030 |
Why?
|
| Consensus | 2 | 2014 | 2935 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 1997 | 644 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 974 | 0.030 |
Why?
|
| Lung | 2 | 2012 | 9826 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 704 | 0.030 |
Why?
|
| Acute Disease | 1 | 2005 | 7141 | 0.030 |
Why?
|
| Syndrome | 1 | 2000 | 3248 | 0.030 |
Why?
|
| Radiology | 2 | 2021 | 2090 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2014 | 1208 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2010 | 357 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 88 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 654 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 874 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 2001 | 930 | 0.030 |
Why?
|
| Infection Control | 1 | 2021 | 962 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 20774 | 0.030 |
Why?
|
| Minority Health | 1 | 2014 | 86 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 162 | 0.030 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2013 | 49 | 0.030 |
Why?
|
| Urinary Catheterization | 1 | 2014 | 201 | 0.030 |
Why?
|
| Philadelphia | 1 | 1993 | 263 | 0.030 |
Why?
|
| Epilepsy, Absence | 1 | 2013 | 48 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 644 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 2790 | 0.030 |
Why?
|
| Brain | 2 | 2012 | 26343 | 0.030 |
Why?
|
| Mannosyltransferases | 1 | 2012 | 23 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2012 | 65 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12017 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2016 | 931 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 20086 | 0.030 |
Why?
|
| Urine | 1 | 2014 | 370 | 0.030 |
Why?
|
| Biology | 1 | 1994 | 292 | 0.030 |
Why?
|
| Research Design | 2 | 2007 | 5979 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1780 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1996 | 839 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2014 | 316 | 0.030 |
Why?
|
| Pregnenediones | 1 | 2011 | 29 | 0.030 |
Why?
|
| Air | 1 | 2012 | 181 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 425 | 0.030 |
Why?
|
| Hospitals, University | 1 | 1993 | 571 | 0.020 |
Why?
|
| Cisplatin | 1 | 1997 | 1637 | 0.020 |
Why?
|
| Genotype | 2 | 2016 | 12946 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 3 | 2009 | 2714 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 346 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2005 | 6191 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2001 | 1794 | 0.020 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2010 | 55 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 417 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 61 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 333 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1997 | 1707 | 0.020 |
Why?
|
| Reoperation | 1 | 2000 | 4200 | 0.020 |
Why?
|
| Epitopes | 1 | 1997 | 2569 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2187 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2699 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2002 | 4029 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2012 | 377 | 0.020 |
Why?
|
| Adenoma | 1 | 2001 | 2168 | 0.020 |
Why?
|
| Ventilators, Mechanical | 1 | 2012 | 292 | 0.020 |
Why?
|
| Transfection | 1 | 1997 | 5892 | 0.020 |
Why?
|
| Phantoms, Imaging | 2 | 2012 | 2466 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1144 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1997 | 2964 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2010 | 142 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 2513 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 2575 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 1182 | 0.020 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2009 | 83 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2013 | 436 | 0.020 |
Why?
|
| Testis | 1 | 1992 | 800 | 0.020 |
Why?
|
| Infant | 3 | 2016 | 35070 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1159 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2000 | 2921 | 0.020 |
Why?
|
| Carrageenan | 1 | 2008 | 66 | 0.020 |
Why?
|
| Atrophy | 1 | 2013 | 1576 | 0.020 |
Why?
|
| Chymases | 1 | 2008 | 99 | 0.020 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2008 | 75 | 0.020 |
Why?
|
| Oncogenes | 1 | 1994 | 1263 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 1483 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 49 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 4646 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Spermatozoa | 1 | 1992 | 625 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2450 | 0.020 |
Why?
|
| Nomograms | 1 | 2010 | 224 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1786 | 0.020 |
Why?
|
| Radioisotope Teletherapy | 1 | 2007 | 18 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 4933 | 0.020 |
Why?
|
| Urinary Fistula | 1 | 2007 | 41 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 657 | 0.020 |
Why?
|
| Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 2866 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 143 | 0.020 |
Why?
|
| Lumbosacral Plexus | 1 | 2007 | 53 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9735 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2007 | 154 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 899 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 124 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1421 | 0.020 |
Why?
|
| Length of Stay | 2 | 2010 | 6294 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 2191 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1188 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2009 | 965 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2012 | 851 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 11363 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 2005 | 149 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 9410 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1999 | 3203 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 941 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 547 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 1423 | 0.020 |
Why?
|
| American Heart Association | 1 | 2010 | 1055 | 0.020 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2005 | 125 | 0.020 |
Why?
|
| Body Composition | 1 | 2014 | 2400 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 1093 | 0.020 |
Why?
|
| Movement | 1 | 2012 | 1470 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1988 | 382 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 2372 | 0.020 |
Why?
|
| Body Burden | 1 | 2005 | 158 | 0.020 |
Why?
|
| DNA Damage | 1 | 1994 | 2423 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 2900 | 0.020 |
Why?
|
| Palliative Care | 1 | 1999 | 3478 | 0.020 |
Why?
|
| Cysts | 1 | 1990 | 676 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 10943 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 1902 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2009 | 770 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 276 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 25575 | 0.020 |
Why?
|
| Video Recording | 1 | 2009 | 944 | 0.010 |
Why?
|
| Leg | 1 | 2009 | 1110 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1992 | 2036 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 8969 | 0.010 |
Why?
|
| Warfarin | 1 | 2012 | 1493 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2010 | 1296 | 0.010 |
Why?
|
| Physical Examination | 1 | 2010 | 1239 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10472 | 0.010 |
Why?
|
| Relative Biological Effectiveness | 1 | 2005 | 323 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 1213 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 163 | 0.010 |
Why?
|
| Ethanol | 1 | 1990 | 1337 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 16665 | 0.010 |
Why?
|
| Motion | 1 | 2006 | 797 | 0.010 |
Why?
|
| Diet | 1 | 2001 | 7923 | 0.010 |
Why?
|
| Continuity of Patient Care | 1 | 2010 | 1048 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2007 | 453 | 0.010 |
Why?
|
| Choice Behavior | 1 | 2008 | 802 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 1415 | 0.010 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 293 | 0.010 |
Why?
|
| Rats | 2 | 2008 | 24265 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 1788 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 2522 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1997 | 3695 | 0.010 |
Why?
|
| Anxiety | 2 | 2010 | 4279 | 0.010 |
Why?
|
| Health Policy | 1 | 2013 | 2657 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 2001 | 327 | 0.010 |
Why?
|
| Mast Cells | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Biophysics | 1 | 2001 | 383 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2001 | 264 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2013 | 3119 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2004 | 403 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2005 | 2003 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 9274 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 3701 | 0.010 |
Why?
|
| Libido | 1 | 1999 | 121 | 0.010 |
Why?
|
| Animals | 4 | 2019 | 168561 | 0.010 |
Why?
|
| Coitus | 1 | 1999 | 133 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16331 | 0.010 |
Why?
|
| Obesity | 1 | 2001 | 12705 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1990 | 2145 | 0.010 |
Why?
|
| Pressure | 1 | 2001 | 1203 | 0.010 |
Why?
|
| Drug Industry | 1 | 2004 | 744 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 1507 | 0.010 |
Why?
|
| Genes, Retinoblastoma | 1 | 1997 | 136 | 0.010 |
Why?
|
| Proteins | 1 | 2012 | 6096 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1994 | 10163 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 12220 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 15494 | 0.010 |
Why?
|
| G1 Phase | 1 | 1997 | 415 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 742 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2001 | 953 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1849 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 7721 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1997 | 701 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1989 | 9144 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1997 | 1096 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15530 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 2455 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2008 | 4681 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1993 | 379 | 0.010 |
Why?
|
| Artifacts | 1 | 2000 | 1903 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2001 | 2968 | 0.010 |
Why?
|
| Mesothelioma | 1 | 1997 | 818 | 0.010 |
Why?
|
| Cell Separation | 1 | 1997 | 1749 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23387 | 0.010 |
Why?
|
| Physicians | 1 | 2008 | 4554 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 4961 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1999 | 2050 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 6313 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2004 | 4229 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1997 | 3420 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 6608 | 0.000 |
Why?
|
| Administration, Cutaneous | 1 | 1990 | 711 | 0.000 |
Why?
|
| Cell Survival | 1 | 1997 | 5872 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1997 | 5975 | 0.000 |
Why?
|
| Alleles | 1 | 1997 | 6931 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1997 | 5978 | 0.000 |
Why?
|
| Drainage | 1 | 1990 | 1140 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1999 | 4249 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 5249 | 0.000 |
Why?
|